Andrew G.  Long net worth and biography

Andrew Long Biography and Net Worth

Andy was appointed Executive Vice President & Chief Financial Officer of Owens & Minor, effective November 11, 2019. Previously, served as CEO of Insys Therapeutics, Inc. Before serving as CEO, Andy was the company’s CFO for two years. Prior to joining Insys Therapeutics, Andy spent two years as SVP of Global Finance for Patheon, a $2 billion private equity-backed provider of contract manufacturing services to the bio-pharma industry. He also served as VP of Global Finance for Thermo Fisher Scientific’s Customer Channels Group. Long holds a Master’s of Business Administration degree in finance, marketing, international business and operations management from the Kellogg Graduate School of Business at Northwestern University and a Bachelor of Science in finance from Indiana University.

How old is Andrew G. Long?

Mr. Long is currently 59 years old. There are 7 older executives and no younger executives at Owens & Minor. The oldest executive at Owens & Minor is Mr. Perry A. Bernocchi, Executive VP & CEO of Patient Direct Segment, who is 65 years old. Learn More on Andrew G. Long's age.

How do I contact Andrew G. Long?

The corporate mailing address for Mr. Long and other Owens & Minor executives is 9120 LOCKWOOD BOULEVARD, MECHANICSVILLE VA, 23261. Owens & Minor can also be reached via phone at (804) 723-7000 and via email at truitt.allcott@owens-minor.com. Learn More on Andrew G. Long's contact information.

Has Andrew G. Long been buying or selling shares of Owens & Minor?

Andrew G. Long has not been actively trading shares of Owens & Minor within the last three months. Learn More on Andrew G. Long's trading history.

Who are Owens & Minor's active insiders?

Owens & Minor's insider roster includes Robert Henkel (Director), Jeffrey Jochims (COO), Jonathan Leon (SVP), Andrew Long (CFO), Michael Lowry (SVP), Shana Neal (Insider), Nicholas Pace (EVP), and Edward Pesicka (CEO). Learn More on Owens & Minor's active insiders.

Are insiders buying or selling shares of Owens & Minor?

During the last year, Owens & Minor insiders bought shares 2 times. They purchased a total of 2,093,412 shares worth more than $19,586,158.48. During the last year, insiders at the sold shares 6 times. They sold a total of 42,205 shares worth more than $749,344.10. The most recent insider tranaction occured on March, 3rd when Major Shareholder Coliseum Capital Management, L bought 354,901 shares worth more than $3,261,540.19. Insiders at Owens & Minor own 3.6% of the company. Learn More about insider trades at Owens & Minor.

Information on this page was last updated on 3/3/2025.

Andrew G. Long Insider Trading History at Owens & Minor

See Full Table

Andrew G. Long Buying and Selling Activity at Owens & Minor

This chart shows Andrew G. Long's buying and selling at Owens & Minor by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1$0Total Insider BuyingTotal Insider Selling

Owens & Minor Company Overview

Owens & Minor logo
Owens & Minor, Inc. is a healthcare solutions company, which engages in the product manufacturing and delivery, home health supply, and perioperative services to support care through the hospital and into the home. It operates through the Products and Healthcare Services, and Patient Direct segments. The Products and Healthcare Services segment includes medical distribution, the outsourced logistics and value-added services business, and global products, which manufacture and source medical surgical products through the production and kitting operations. The Patient Direct segment includes the home healthcare business, Byram and Apria. The company was founded by Otho O. Owens and G. Gilmer Minor in 1882 and is headquartered in Henrico County, VA.
Read More

Today's Range

Now: $8.60
Low: $8.40
High: $8.87

50 Day Range

MA: $9.84
Low: $6.23
High: $15.09

2 Week Range

Now: $8.60
Low: $6.07
High: $28.35

Volume

1,423,062 shs

Average Volume

1,013,218 shs

Market Capitalization

$664.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.61